| 產(chǎn)品編號 | bs-16912R-Cy7 |
| 英文名稱1 | Rabbit Anti-KCNQ3/Cy7 Conjugated antibody |
| 中文名稱 | Cy7標(biāo)記的電壓門控鉀通道亞基Kv7.3抗體 |
| 別 名 | BFNC 2; BFNC; BFNC2; EBN 2; EBN2; KCNQ 3; KCNQ3; KCNQ3_HUMAN; KQT like 3; KQT-like 3; KV7.3; Potassium channel subunit alpha KvLQT3; Potassium channel voltage gated subfamily Q member 3; Potassium voltage gated channel KQT like protein 3; Potassium voltage gated channel KQT like subfamily member 3; Potassium voltage gated channel subfamily KQT member 3; Potassium voltage-gated channel subfamily KQT member 3; Voltage gated potassium channel subunit Kv7.3; Voltage-gated potassium channel subunit Kv7.3. |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 細(xì)胞生物 神經(jīng)生物學(xué) 通道蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 97kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human KCNQ3 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and one of two related proteins encoded by the KCNQ2 and KCNQ5 genes, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2). Two variants encoding distinct isoforms have been found. [provided by RefSeq, Mar 2011] Function: Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. Subcellular Location: Membrane. Tissue Specificity: Predominantly expressed in brain. DISEASE: Defects in KCNQ3 are the cause of benign neonatal epilepsy type 2 (EBN2) [MIM:121201]. Benign neonatal epilepsy is characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset. Similarity: Belongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.3/KCNQ3 sub-subfamily. Database links: Entrez Gene: 3786 Human Entrez Gene: 110862 Mouse Omim: 602232 Human SwissProt: O43525 Human SwissProt: Q8K3F6 Mouse Unigene: 374023 Human Unigene: 255585 Mouse Unigene: 205060 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
